Leids Universitair Medisch Centrum (LUMC) — Clinical Trial Site

21 Registered trials

6 Currently recruiting

Organisation

Leids Universitair Medisch Centrum (LUMC)

Location

Leiden, Netherlands

Identifier

ORG-100047879

Address

Albinusdreef 2, 2333 ZA, Netherlands

Departments

#3713: Cardiology
Anesthesiology
Cardiology
Department of Pulmonary Diseases
Department of Surgery
Gynaecology
Hematology
ICU
Intensive Care
Medical oncology
Medische Oncologie
Neurology
Oncology
Pulmonary Diseases
Pulmonology
Trombosis & Hemostatis

Clinical trials at this site (21)

Search interface

RATE: Reduced anticoagulation targets in extracorporeal life support Pending

2023-509675-16-01 All patients who receive ECMO treatment during the stud 5
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting

2023-506886-76-00 ALK positive non-small cell lung cancer 6 2022-03-23
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac… Recruiting

2023-507801-32-00 Isolated Subsegmental Pulmonary Embolism 6 2026-04-22
PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized… Recruiting

2023-504144-33-01 esophageal cancer 11 2024-10-17
Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting

2023-508139-29-00 Advanced or metastatic solid tumors 7 2024-06-26
A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting

2023-507460-39-00 Adult patients with resectable muscle-invasive urotheli 10 2024-02-15
FIGO 2018 stage IB2 (>2 cm - ≤4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa)… Recruiting

2023-507230-24-00 Cervical cancer 4 2021-02-17
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stroma… Ended

2022-501477-40-00 Advanced Gastrointestinal Stromal Tumor 3 2024-06-25
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intrav… Ended

2023-506737-30-00 Duchenne Muscular Dystrophy 7 2024-03-08
Effects of BBP-418 (ribitol) in Patients with LGMD2I Ended

2023-503379-33-01 Limb Girdle Muscular Dystrophy 2I/R9 5 2024-02-12
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt… Ended

2023-504628-24-00 Huntington's Disease 4 2023-10-31
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle… Ended

2023-509380-24-00 Metastatic upper gastrointestinal cancer, cancer of eso 4 2021-11-01
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended

2023-509287-26-00 previously untreated metastatic or locally advanced eso 4 2019-07-01
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
Comparison of multiple doses of intramuscular versus intranasal naloxone for reversal of opioid toxicity Ended

2023-505338-93-00 Healthy volunteers 4 2023-09-21
A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D… Ended

2023-509835-26-00 Huntington’s Disease 4 2022-07-06
A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended

2023-507271-21-00 Follicular Lymphoma 5 2017-04-11